Autolus Therapeutics PLC
NASDAQ:AUTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Autolus Therapeutics PLC
Pre-Tax Income
Autolus Therapeutics PLC
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Pre-Tax Income
-$285.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Pre-Tax Income
-£19.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Pre-Tax Income
-$290.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Pre-Tax Income
£64.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Pre-Tax Income
-£31.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-7%
|
|
|
Niox Group PLC
LSE:NIOX
|
Pre-Tax Income
£11.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
Glance View
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
See Also
What is Autolus Therapeutics PLC's Pre-Tax Income?
Pre-Tax Income
-285.6m
USD
Based on the financial report for Dec 31, 2025, Autolus Therapeutics PLC's Pre-Tax Income amounts to -285.6m USD.
What is Autolus Therapeutics PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-11%
Over the last year, the Pre-Tax Income growth was -30%. The average annual Pre-Tax Income growth rates for Autolus Therapeutics PLC have been -18% over the past three years , -11% over the past five years .
